Samus Therapeutics, Inc.

Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees

Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s and chronic traumatic encephalopathy. Samus was established by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Laboratory at the Memorial Sloan Kettering Cancer Center, and at Rockefeller University and Weill Cornell Medicine, and is led by Jonathan Lewis, MD, PhD, Chief Executive Officer. The Company’s lead oncology program, epichaperome complex inhibitor PU-H71, is being evaluated in Phase 1b and 1b/2 clinical studies in breast cancer and myelofibrosis. The Company’s lead CNS program, neurodegenerative epichaperome complex inhibitor PU-AD, is being studied in a biomarker study evaluating the distribution of the epichaperome complex in the brain of subjects with Alzheimer’s disease, with a Phase 1 therapeutic study to follow in 2018. In parallel with its therapeutics program, Samus is advancing the companion neurology and oncology PET/SPECT and flow cytometry biomarker programs PU-PET/SPECT and PU-CYT.

To learn more about Samus Therapeutics, email:
info@samustherapeutics.com

Sign up for free to view info

Email Format Employee directory